Table 1 Humoral immunogenicity outcomes against wild-type SARS-CoV-2 after the third dose of BNT162b2 in the evaluable analysis population
Adolescents three doses | Adults three doses | |
|---|---|---|
S IgG on ELISA | ||
N | 28 | 28 |
GM-OD450 value (95% CI) | 1.39 (1.32–1.48) | 1.44 (1.40–1.48) |
% positive (≥LOD at 0.3) | 100%, P > 0.9999 | 100% |
S-RBD IgG on ELISA | ||
N | 28 | 33 |
GM-OD450 value (95% CI) | 2.89 (2.85–2.93) | 2.93 (2.85–3.01) |
% positive (≥LOD at 0.5) | 100%, P > 0.9999 | 100% |
S-RBD ACE2-blocking antibody on sVNT | ||
N | 25 | 33 |
GM % inhibition (95% CI) | 97.1% (97.0–97.2%) | 97.0% (96.9–97.1%) |
% positive (≥LOQ at 30%) | 100%, P > 0.9999 | 100% |
Neutralising antibody on PRNT | ||
N | 14 | 14 |
GM-PRNT90 (95% CI) | 263 (218–317) | 215 (166–279) |
% positive (≥LOD at 10) | 100%, P > 0.9999 | 100% |
GM-PRNT50 (95% CI) | 320 (320–320) | 320 (320–320) |
% positive (≥LOD at 10) | 100%, P > 0.9999 | 100% |
S IgG avidity on ELISA | ||
N | 28 | 28 |
GM avidity index (95% CI) | 88.8% (85.8.8–91.9) | 81.0% (77.7–84.4) |
S IgG FcγRIIIa-binding on ELISA | ||
N | 28 | 28 |
GM-OD450 value (95% CI) | 1.90 (1.86–1.93%) | 1.87 (1.85–1.89%) |
% positive (≥LOD at 0.28) | 100%, >0.9999 | 100% |
